Symbols

EDIT

Editas Medicine·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 2

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Significant Revenue Decline

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About EDIT

Editas Medicine, Inc.

A leading genome editing company pioneering CRISPR technology for treating serious diseases

Industry

Biological Technology

Established Date

Listing Date

02/03/2016

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.editasmedicine.com

Security Type

Common stock

Office address

11 Hurley Street , Cambridge , Massachusetts 02141

Business

Introduction

Editas Medicine, Inc., was founded in September 2013 as Gengine, Inc., and later changed its name to Editas Medicine, Inc., in November 2013. The company is a leading genetic research company dedicated to treating gene-related diseases by correcting patients' disease-causing genes.

Company Financials

EPS

EDIT has released its 2025 Q4 earnings. EPS was reported at -0.06, versus the expected -0.24, beating expectations. The chart below visualizes how EDIT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

EDIT has released its 2025 Q4 earnings report, with revenue of 24.74M, reflecting a YoY change of -19.16%, and net profit of -5.62M, showing a YoY change of 87.62%. The Sankey diagram below clearly presents EDIT's revenue sources and cost distribution.